海普瑞(09989)发布公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液(商品名：Ivenoxin)已获得南非健康产品监管局(SAHPRA)上市许可。

此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。未来，集团将持续发力加速全球市场拓展与销售管道建设，为深化海外市场发展奠定基础。

截至本公告日，集团依诺肝素钠制剂已获准在中国、美国、欧盟、英国、瑞士、波兰、巴西、哥伦比亚、智利、加拿大、沙乌地阿拉伯、阿联酋、马来西亚、澳大利亚、纽西兰、泰国、阿根廷等全球50多个国家和地区销售。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.